<?xml version="1.0" encoding="UTF-8"?>
<patent-document ucid="EP-2959899-A1" country="EP" doc-number="2959899" kind="A1" date="20151230" family-id="46826905" file-reference-id="315090" date-produced="20180825" status="corrected" lang="EN"><bibliographic-data><publication-reference fvid="160452779" ucid="EP-2959899-A1"><document-id><country>EP</country><doc-number>2959899</doc-number><kind>A1</kind><date>20151230</date><lang>EN</lang></document-id></publication-reference><application-reference ucid="EP-15168972-A" is-representative="NO"><document-id mxw-id="PAPP193868526" load-source="docdb" format="epo"><country>EP</country><doc-number>15168972</doc-number><kind>A</kind><date>20120823</date><lang>EN</lang></document-id><document-id mxw-id="PAPP193868527" load-source="patent-office" format="original"><country>EP</country><doc-number>15168972.6</doc-number><date>20120823</date><lang>EN</lang></document-id></application-reference><priority-claims><priority-claim mxw-id="PPC162030700" ucid="EP-12756594-A" linkage-type="3" load-source="docdb"><document-id format="epo"><country>EP</country><doc-number>12756594</doc-number><kind>A</kind><date>20120823</date></document-id></priority-claim><priority-claim mxw-id="PPC162035834" ucid="US-201161526440-P" load-source="docdb"><document-id format="epo"><country>US</country><doc-number>201161526440</doc-number><kind>P</kind><date>20110823</date></document-id></priority-claim></priority-claims><technical-data><classifications-ipcr><classification-ipcr mxw-id="PCL-1915427408" load-source="docdb">A61K  31/381       20060101AFI20160719BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL-1915429780" load-source="docdb">A61P  27/02        20060101ALI20160719BHEP        </classification-ipcr></classifications-ipcr><classifications-cpc><classification-cpc mxw-id="PCL-1987764512" load-source="docdb" scheme="CPC">A61K  31/381       20130101 FI20141031BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1987797088" load-source="docdb" scheme="CPC">A61K  45/06        20130101 LI20141030BHEP        </classification-cpc></classifications-cpc><invention-title mxw-id="PT165549803" lang="DE" load-source="patent-office">VERWENDUNG VON ZILEUTON ZUR BEHANDLUNG VON NASENPOLYPEN BEI PATIENTEN MIT ZYSTISCHER FIBROSE</invention-title><invention-title mxw-id="PT165549804" lang="EN" load-source="patent-office">USE OF ZILEUTON FOR THE TREATMENT OF NASAL POLYPS IN CYSTIC FIBROSIS PATIENTS</invention-title><invention-title mxw-id="PT165549805" lang="FR" load-source="patent-office">UTILISATION DE ZILEUTON POUR LE TRAITEMENT DE POLYPES NASAUX CHEZ PATIENTS ATTEINTS DE FIBROSE CYSTIQUE</invention-title><citations><patent-citations><patcit mxw-id="PCIT335964424" load-source="docdb" ucid="US-3536809-A"><document-id format="epo"><country>US</country><doc-number>3536809</doc-number><kind>A</kind><date>19701027</date></document-id><sources><source name="APP" created-by-npl="N"/></sources></patcit><patcit mxw-id="PCIT335964425" load-source="docdb" ucid="US-3598123-A"><document-id format="epo"><country>US</country><doc-number>3598123</doc-number><kind>A</kind><date>19710810</date></document-id><sources><source name="APP" created-by-npl="N"/></sources></patcit><patcit mxw-id="PCIT335964426" load-source="docdb" ucid="US-3845770-A"><document-id format="epo"><country>US</country><doc-number>3845770</doc-number><kind>A</kind><date>19741105</date></document-id><sources><source name="APP" created-by-npl="N"/></sources></patcit><patcit mxw-id="PCIT335964427" load-source="docdb" ucid="US-3916899-A"><document-id format="epo"><country>US</country><doc-number>3916899</doc-number><kind>A</kind><date>19751104</date></document-id><sources><source name="APP" created-by-npl="N"/></sources></patcit><patcit mxw-id="PCIT335964428" load-source="docdb" ucid="US-4008719-A"><document-id format="epo"><country>US</country><doc-number>4008719</doc-number><kind>A</kind><date>19770222</date></document-id><sources><source name="APP" created-by-npl="N"/></sources></patcit><patcit mxw-id="PCIT421366785" load-source="docdb" ucid="US-4873259-A"><document-id format="epo"><country>US</country><doc-number>4873259</doc-number><kind>A</kind><date>19891010</date></document-id><sources><source name="APP" created-by-npl="N"/><source name="SEA" category="AD" created-by-npl="N"/></sources></patcit><patcit mxw-id="PCIT335964431" load-source="docdb" ucid="US-5059595-A"><document-id format="epo"><country>US</country><doc-number>5059595</doc-number><kind>A</kind><date>19911022</date></document-id><sources><source name="APP" created-by-npl="N"/></sources></patcit><patcit mxw-id="PCIT335964432" load-source="docdb" ucid="US-5073543-A"><document-id format="epo"><country>US</country><doc-number>5073543</doc-number><kind>A</kind><date>19911217</date></document-id><sources><source name="APP" created-by-npl="N"/></sources></patcit><patcit mxw-id="PCIT335964433" load-source="docdb" ucid="US-5120548-A"><document-id format="epo"><country>US</country><doc-number>5120548</doc-number><kind>A</kind><date>19920609</date></document-id><sources><source name="APP" created-by-npl="N"/></sources></patcit><patcit mxw-id="PCIT335964434" load-source="docdb" ucid="US-5354556-A"><document-id format="epo"><country>US</country><doc-number>5354556</doc-number><kind>A</kind><date>19941011</date></document-id><sources><source name="APP" created-by-npl="N"/></sources></patcit><patcit mxw-id="PCIT335964435" load-source="docdb" ucid="US-5591767-A"><document-id format="epo"><country>US</country><doc-number>5591767</doc-number><kind>A</kind><date>19970107</date></document-id><sources><source name="APP" created-by-npl="N"/></sources></patcit><patcit mxw-id="PCIT335964436" load-source="docdb" ucid="US-5639476-A"><document-id format="epo"><country>US</country><doc-number>5639476</doc-number><kind>A</kind><date>19970617</date></document-id><sources><source name="APP" created-by-npl="N"/></sources></patcit><patcit mxw-id="PCIT335964437" load-source="docdb" ucid="US-5663368-A"><document-id format="epo"><country>US</country><doc-number>5663368</doc-number><kind>A</kind><date>19970902</date></document-id><sources><source name="APP" created-by-npl="N"/></sources></patcit><patcit mxw-id="PCIT335964438" load-source="docdb" ucid="US-5674533-A"><document-id format="epo"><country>US</country><doc-number>5674533</doc-number><kind>A</kind><date>19971007</date></document-id><sources><source name="APP" created-by-npl="N"/></sources></patcit><patcit mxw-id="PCIT335964439" load-source="docdb" ucid="US-5733566-A"><document-id format="epo"><country>US</country><doc-number>5733566</doc-number><kind>A</kind><date>19980331</date></document-id><sources><source name="APP" created-by-npl="N"/></sources></patcit><patcit mxw-id="PCIT335964440" load-source="docdb" ucid="US-6080874-A"><document-id format="epo"><country>US</country><doc-number>6080874</doc-number><kind>A</kind><date>20000627</date></document-id><sources><source name="APP" created-by-npl="N"/></sources></patcit><patcit mxw-id="PCIT335964441" load-source="docdb" ucid="WO-2007098189-A2"><document-id format="epo"><country>WO</country><doc-number>2007098189</doc-number><kind>A2</kind><date>20070830</date></document-id><sources><source name="SEA" category="A" created-by-npl="N"/></sources></patcit></patent-citations><non-patent-citations><nplcit><text>BASHA ET AL., J ORG. CHEM., vol. 59, no. 20, 1994, pages 6103 - 6</text><sources><source mxw-id="PNPL57938983" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>BATSAKIS; EI-NAGGAR, ANN. OTOL. RHINOL. LARYNGOL., vol. 105, 1996, pages 329 - 330</text><sources><source mxw-id="PNPL57938984" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>BECKER ET AL., AM J RHINOL, vol. 21, 2007, pages 478 - 482</text><sources><source mxw-id="PNPL57938985" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>BRIHAYE ET AL., INT J PEDIATR OTORHINOLARYNGOL., vol. 28, no. 2-3, January 1994 (1994-01-01), pages 141 - 7</text><sources><source mxw-id="PNPL57938986" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>BRIHAYE ET AL., INT. J. PEDIATR. OTORHINOLARYNGOL., vol. 28, no. 2-3, 1994, pages 141 - 147</text><sources><source mxw-id="PNPL57938987" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>CIMMINO ET AL., CLIN OTOLARYNGOL, vol. 28, 2003, pages 125 - 132</text><sources><source mxw-id="PNPL57938988" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>CLAEYS ET AL., CLIN. EXP. ALLERGY, vol. 35, 2005, pages 467 - 472</text><sources><source mxw-id="PNPL57938989" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>CLAEYS S ET AL: "Nasal polyps in patients with and without cystic fibrosis: a differentiation by innate markers and inflammatory mediators.", CLINICAL AND EXPERIMENTAL ALLERGY : JOURNAL OF THE BRITISH SOCIETY FOR ALLERGY AND CLINICAL IMMUNOLOGY APR 2005 LNKD- PUBMED:15836755, vol. 35, no. 4, April 2005 (2005-04-01), pages 467 - 472, XP002685304, ISSN: 0954-7894</text><sources><source mxw-id="PNPL57938990" load-source="docdb" name="SEA" category="A"/></sources></nplcit><nplcit><text>COSTE ET AL., RHINOLOGY, vol. 33, 1995, pages 152 - 156</text><sources><source mxw-id="PNPL57938991" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>DEGAUDEMAR ET AL., RHINOLOGY, vol. 34, 1996, pages 194 - 197</text><sources><source mxw-id="PNPL57938992" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>FOKKENS ET AL., RHINOLOGY, vol. 45, no. 20, 16 October 2007 (2007-10-16), pages 1 - 139, XP008091259</text><sources><source mxw-id="PNPL57938993" load-source="docdb" name="SEA" category="AD"/></sources></nplcit><nplcit><text>FOKKENS ET AL., RHINOLOGY, vol. 45, no. 20, pages 1 - 139</text><sources><source mxw-id="PNPL57938994" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>FRIEDMAN; STEWART, AM. J. RHINOL., vol. 20, 2006, pages 568 - 72</text><sources><source mxw-id="PNPL57938995" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>GARIGIPATI ET AL., TETRAHEDRON LETTERS, vol. 34, no. 35, 1993, pages 5537 - 40</text><sources><source mxw-id="PNPL57938996" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>GYSIN ET AL., PEDIATR PULMONOL, vol. 30, 2000, pages 481 - 489</text><sources><source mxw-id="PNPL57938997" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>HADFIELD ET AL., CLIN OTOLARYNGOL ALLIED SCI., vol. 25, 2000, pages 19 - 22</text><sources><source mxw-id="PNPL57938998" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>HADFIELD ET AL., CLIN. OTOLARYNGOL ALLIED SCI., vol. 25, 2000, pages 19 - 22</text><sources><source mxw-id="PNPL57938999" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>HADFIELD ET AL., RHINOLOGY, vol. 38, 2000, pages 63 - 5</text><sources><source mxw-id="PNPL57939000" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>HENRIKSSON ET AL., CHEST, vol. 121, 2002, pages 40 - 47</text><sources><source mxw-id="PNPL57939001" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>HENRIKSSON ET AL., CHEST, vol. 121, 2002, pages 40 - 47, XP002685306</text><sources><source mxw-id="PNPL57939002" load-source="docdb" name="SEA" category="AD"/></sources></nplcit><nplcit><text>HISAO ET AL., TETRAHEDRON LETTERS, vol. 33, no. 19, 1992, pages 2629 - 32</text><sources><source mxw-id="PNPL57939003" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>JORISSEN ET AL., AM. J. RESPIR. CRIT. CARE MED., vol. 159, 1999, pages 1412 - 1416</text><sources><source mxw-id="PNPL57939004" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>KERREBIJN ET AL., EUR RESPIR J., vol. 5, 1992, pages 1239 - 42</text><sources><source mxw-id="PNPL57939005" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>KERREBIJN ET AL., EUR. RESPIR. J., vol. 5, 1992, pages 1239 - 42</text><sources><source mxw-id="PNPL57939006" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>MCCLAY, NASAL POLYPS, E-MEDICINE SPECIALTIES REVIEW, 22 October 2008 (2008-10-22), Retrieved from the Internet &lt;URL:http://emedicine.medscape.com/article/994274-treatment&gt;</text><sources><source mxw-id="PNPL80272361" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>MYGIND; LUND, TREAT RESPIR MED., vol. 5, 2006, pages 93 - 102</text><sources><source mxw-id="PNPL57939008" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>PAR STJARNE ET AL., ARCH OTOLARYNGOL HEAD NECK SURG., vol. 132, 2006, pages 179 - 185</text><sources><source mxw-id="PNPL57939009" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>PARNES S M ET AL: "Acute effects of antileukotrienes on sinonasal polyposis and sinusitis.", EAR, NOSE, &amp; THROAT JOURNAL JAN 2000 LNKD- PUBMED:10665187, vol. 79, no. 1, January 2000 (2000-01-01), pages 18 - 20 , 24, XP009163737, ISSN: 0145-5613</text><sources><source mxw-id="PNPL57939010" load-source="docdb" name="SEA" category="A"/></sources></nplcit><nplcit><text>PIMENTA ET AL., INTL. ARCH. OTORHINOLARYNGOL., vol. 12, 2008, pages 552 - 558</text><sources><source mxw-id="PNPL57939011" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>SAKANO ET AL., INT. J. PEDIATR. OTORHINOLARYNGOL, vol. 71, 2007, pages 41 - 50</text><sources><source mxw-id="PNPL57939012" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>SCADDING, CURRALLERGY ASTHMA REP., vol. 2, 2002, pages 494 - 9</text><sources><source mxw-id="PNPL57939013" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>SHEAHAN, RJ. HARVEY; RJ SCHLOSSER: "Book chapter Nasal Polyps: pathogenesis, medical and surgical treatment", 2010, article "Nasal polyps in Cystic Fibrosis", pages: 145 - 152</text><sources><source mxw-id="PNPL57939014" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>SMALL ET AL., ALLERGY CLIN IMMUNOL, vol. 116, 2005, pages 1275 - 81</text><sources><source mxw-id="PNPL57939015" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>SMALL ET AL., J. ALLERGY CLIN. IMMUNOL., vol. 116, no. 6, 2005, pages 1275 - 1281</text><sources><source mxw-id="PNPL57939016" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>STEWART ET AL., OTOLARYNGOLOGY - HEAD AND NECK SURGERY, vol. 130, no. 2, 2004, pages 157 - 163</text><sources><source mxw-id="PNPL57939017" load-source="docdb" name="APP"/></sources></nplcit><nplcit><text>TANIGUCHI ET AL., ALLERGOLOGY INTERNATIONAL, vol. 57, 2008, pages 313 - 320</text><sources><source mxw-id="PNPL57939018" load-source="docdb" name="APP"/></sources></nplcit></non-patent-citations></citations></technical-data><related-documents><relation type="division"><child-doc ucid="EP-15168972-A"><document-id load-source="patent-office" format="epo"><country>EP</country><doc-number>15168972</doc-number><kind>A</kind><date>20120823</date></document-id><document-id load-source="patent-office" format="original"><country>EP</country><doc-number>15168972.6</doc-number><date>20120823</date></document-id></child-doc><parent-doc ucid="EP-12756594-A"><document-id load-source="patent-office" format="epo"><country>EP</country><doc-number>12756594</doc-number><kind>A</kind><date>20120823</date></document-id><document-id load-source="patent-office" format="original"><country>EP</country><doc-number>12756594.3</doc-number><date>20120823</date></document-id><parent-grant-document ucid="EP-2747762-B1"><document-id><country>EP</country><doc-number>2747762</doc-number><kind>B1</kind><date>20150701</date></document-id></parent-grant-document></parent-doc></relation></related-documents><parties><applicants><applicant mxw-id="PPAR1103335845" load-source="docdb" sequence="1" format="epo"><addressbook><last-name>CORNERSTONE THERAPEUTICS INC</last-name><address><country>US</country></address></addressbook></applicant><applicant mxw-id="PPAR1103323461" load-source="docdb" sequence="1" format="intermediate"><addressbook><last-name>CORNERSTONE THERAPEUTICS INC.</last-name></addressbook></applicant><applicant mxw-id="PPAR1101643456" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>Cornerstone Therapeutics Inc.</last-name><iid>101153871</iid><address><street>1255 Crescent Green Drive Suite 250</street><city>Cary, North Carolina 27518</city><country>US</country></address></addressbook></applicant><applicant mxw-id="PPAR1103330212" load-source="docdb" sequence="2" format="epo"><addressbook><last-name>HAN JOSEPH K</last-name><address><country>US</country></address></addressbook></applicant><applicant mxw-id="PPAR1103323427" load-source="docdb" sequence="2" format="intermediate"><addressbook><last-name>HAN, Joseph, K.</last-name></addressbook></applicant><applicant mxw-id="PPAR1101652025" load-source="patent-office" sequence="2" format="original"><addressbook><last-name>Han, Joseph, K.</last-name><iid>101368717</iid><address><street>2617 Britannica Place</street><city>Virginia Beach, VA 23454</city><country>US</country></address></addressbook></applicant></applicants><inventors><inventor mxw-id="PPAR1103314558" load-source="docdb" sequence="1" format="epo"><addressbook><last-name>HAN JOSEPH K</last-name><address><country>US</country></address></addressbook></inventor><inventor mxw-id="PPAR1103311163" load-source="docdb" sequence="1" format="intermediate"><addressbook><last-name>HAN, JOSEPH K.</last-name></addressbook></inventor><inventor mxw-id="PPAR1101641199" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>HAN, JOSEPH K.</last-name><address><street>2617 Britannica Place</street><city>VIRGINIA BEACH, VA Virginia 23454</city><country>US</country></address></addressbook></inventor><inventor mxw-id="PPAR1103312507" load-source="docdb" sequence="2" format="epo"><addressbook><last-name>DELL ANNA CARMEN</last-name><address><country>US</country></address></addressbook></inventor><inventor mxw-id="PPAR1103317508" load-source="docdb" sequence="2" format="intermediate"><addressbook><last-name>DELL'ANNA, CARMEN</last-name></addressbook></inventor><inventor mxw-id="PPAR1101650684" load-source="patent-office" sequence="2" format="original"><addressbook><last-name>DELL'ANNA, CARMEN</last-name><address><street>1419 Crocker Station</street><city>Houston TX 77019</city><country>US</country></address></addressbook></inventor></inventors><agents><agent mxw-id="PPAR1101643255" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>Potter Clarkson LLP</last-name><iid>101340609</iid><address><street>The Belgrave Centre Talbot Street</street><city>Nottingham NG1 5GG</city><country>GB</country></address></addressbook></agent></agents></parties><international-convention-data><designated-states><ep-contracting-states><country mxw-id="DS660628681" load-source="docdb">AL</country><country mxw-id="DS660713474" load-source="docdb">AT</country><country mxw-id="DS660628682" load-source="docdb">BE</country><country mxw-id="DS660789976" load-source="docdb">BG</country><country mxw-id="DS660629125" load-source="docdb">CH</country><country mxw-id="DS660706484" load-source="docdb">CY</country><country mxw-id="DS660713551" load-source="docdb">CZ</country><country mxw-id="DS660628695" load-source="docdb">DE</country><country mxw-id="DS660706485" load-source="docdb">DK</country><country mxw-id="DS660706486" load-source="docdb">EE</country><country mxw-id="DS660730587" load-source="docdb">ES</country><country mxw-id="DS660789977" load-source="docdb">FI</country><country mxw-id="DS660629126" load-source="docdb">FR</country><country mxw-id="DS660628696" load-source="docdb">GB</country><country mxw-id="DS660706491" load-source="docdb">GR</country><country mxw-id="DS660628697" load-source="docdb">HR</country><country mxw-id="DS660713552" load-source="docdb">HU</country><country mxw-id="DS660628085" load-source="docdb">IE</country><country mxw-id="DS660706492" load-source="docdb">IS</country><country mxw-id="DS660629135" load-source="docdb">IT</country><country mxw-id="DS660706493" load-source="docdb">LI</country><country mxw-id="DS660789978" load-source="docdb">LT</country><country mxw-id="DS660707583" load-source="docdb">LU</country><country mxw-id="DS660789979" load-source="docdb">LV</country><country mxw-id="DS660789980" load-source="docdb">MC</country><country mxw-id="DS660707584" load-source="docdb">MK</country><country mxw-id="DS660707585" load-source="docdb">MT</country><country mxw-id="DS660707586" load-source="docdb">NL</country><country mxw-id="DS660629136" load-source="docdb">NO</country><country mxw-id="DS660707591" load-source="docdb">PL</country><country mxw-id="DS660628086" load-source="docdb">PT</country><country mxw-id="DS660730588" load-source="docdb">RO</country><country mxw-id="DS660628091" load-source="docdb">RS</country><country mxw-id="DS660707592" load-source="docdb">SE</country><country mxw-id="DS660628698" load-source="docdb">SI</country><country mxw-id="DS660629137" load-source="docdb">SK</country><country mxw-id="DS660629138" load-source="docdb">SM</country><country mxw-id="DS660706494" load-source="docdb">TR</country></ep-contracting-states></designated-states></international-convention-data></bibliographic-data><abstract mxw-id="PA166480877" lang="EN" load-source="patent-office"><p id="pa01" num="0001">The present invention provides methods of treating nasal polyps in cystic fibrosis patients using zileuton. The present invention also provides methods of treating nasal polyps in cystic fibrosis patients using zileuton in combination with surgical debridement and/or steroid treatment.</p></abstract><abstract mxw-id="PA166760689" lang="EN" source="EPO" load-source="docdb"><p>The present invention provides methods of treating nasal polyps in cystic fibrosis patients using zileuton. The present invention also provides methods of treating nasal polyps in cystic fibrosis patients using zileuton in combination with surgical debridement and/or steroid treatment.</p></abstract><description mxw-id="PDES98405578" lang="EN" load-source="patent-office"><!-- EPO <DP n="1"> --><heading id="h0001"><b>Related Applications</b></heading><p id="p0001" num="0001">This application claims priority to <patcit id="pcit0001" dnum="US61526440A"><text>U.S. Provisional Application No. 61/526,440, filed on August 23, 2011</text></patcit>, the entire contents of which are hereby incorporated herein by reference.</p><heading id="h0002"><b>Background of the Invention</b></heading><p id="p0002" num="0002">Cystic fibrosis (CF) is the most common autosomal recessive condition resulting in morbidity and mortality among Caucasians, affecting about 30,000 children and adults in the United States. Adult CF patients (18 years and older) have been estimated to number about 47% of this total in 2009, or approximately 14,000 individuals (<nplcit id="ncit0001" npl-type="s"><text>Taniguchi et al., Allergology International, 57:313-320, 2008</text></nplcit> and Cystic Fibrosis Foundation website). Cystic fibrosis is caused by mutations in the CF transmembrane conductance regulator gene (CFTR) which encodes for a protein that functions as a cyclic adenosine monophosphate-regulated chloride channel (<nplcit id="ncit0002" npl-type="s"><text>Henriksson et al., Chest, 121:40-47, 2002</text></nplcit>). Abnormal function of this protein results in aberrant conductance across the apical membrane of the epithelial cells of the lung, pancreas, sweat glands, liver, salivary glands, colon and nasal mucosa (Henriksson <i>et al</i>., 2002). The resultant dysfunction of the mucosal interface of the upper respiratory tract is clinically manifest as frequent otorhinolaryngological manifestations of CF, including chronic rhinosinusitis and nasosinusal polyposis (<nplcit id="ncit0003" npl-type="s"><text>Claeys et al., Clin. Exp. Allergy, 35:467-472, 2005</text></nplcit>). Although these conditions do not result in mortality, they cause considerable morbidity and negatively impact the quality of life of many CF patients due to symptomatology (<nplcit id="ncit0004" npl-type="s"><text>Pimenta et al., Intl. Arch. Otorhinolaryngol., 12:552-558, 2008</text></nplcit>).</p><p id="p0003" num="0003">Nasal polyps are polypoidal masses arising mainly as overgrowths from the mucous membranes of the nose and paranasal sinuses and are often freely movable and nontender. Antrochoanal polyps arise from the maxillary sinuses and are typically single and unilateral, while ethmoidal polyps arise from the ethmoidal sinuses and are typically multiple and bilateral. Compared to the general population, the prevalence of nasal polyps (NPs) is considerably higher in CF patients (Table 1), ranging from 32 to 56% of patients (Henriksson <i>et al.,</i> 2002; <nplcit id="ncit0005" npl-type="s"><text>Coste et al., Rhinology, 33:152-156, 1995</text></nplcit>; <nplcit id="ncit0006" npl-type="s"><text>Kerrebijn et al., Eur. Respir. J., 5:1239-42, 1992</text></nplcit>; <nplcit id="ncit0007" npl-type="s"><text>Brihaye et al., Int. J. Pediatr. Otorhinolaryngol., 28(2-3):141-147, 1994</text></nplcit>; <nplcit id="ncit0008" npl-type="s"><text>Hadfield et al., Clin. Otolaryngol Allied Sci.,<!-- EPO <DP n="2"> --> 25:19-22, 2000</text></nplcit>; <nplcit id="ncit0009" npl-type="s"><text>DeGaudemar et al., Rhinology, 34:194-197, 1996</text></nplcit>;<nplcit id="ncit0010" npl-type="s"><text> Jorissen et al., Am. J. Respir. Crit. Care Med., 159:1412-1416, 1999</text></nplcit>;<nplcit id="ncit0011" npl-type="s"><text> Sakano et al., Int. J. Pediatr. Otorhinolaryngol, 71:41-50, 2007</text></nplcit>).
<tables id="tabl0001" num="0001"><table frame="all"><title>Table 1: <i>Literature reporting prevalence of nasal polyps in patients with CF</i></title><tgroup cols="4"><colspec colnum="1" colname="col1" colwidth="51mm"/><colspec colnum="2" colname="col2" colwidth="31mm"/><colspec colnum="3" colname="col3" colwidth="32mm"/><colspec colnum="4" colname="col4" colwidth="39mm"/><thead><row><entry align="center" valign="top">MEAN AGE (yrs)</entry><entry align="center" valign="top">AGE RANGE (yrs)</entry><entry align="center" valign="top">PREVALENCE (%)</entry><entry align="center" valign="top">REFERENCE</entry></row></thead><tbody><row><entry align="center">13.5</entry><entry align="center">13 months-31 yrs</entry><entry align="center">44</entry><entry align="center">Coste <i>et al</i>., 1995</entry></row><row><entry align="center">26</entry><entry align="center">17-40</entry><entry align="center">44</entry><entry align="center">Kerrebijn <i>et al.,</i> 1992</entry></row><row><entry align="center">15</entry><entry align="center">5-34</entry><entry align="center">45</entry><entry align="center">Brihaye <i>et al.,</i> 1994</entry></row><row><entry align="center">28</entry><entry align="center">16-58</entry><entry align="center">37</entry><entry align="center">Hadfield <i>et al.,</i> 2000</entry></row><row><entry align="center">10</entry><entry align="center">1-23</entry><entry align="center">32</entry><entry align="center">DeGaudemar <i>et al.,</i> 1996</entry></row><row><entry align="center">18±8</entry><entry align="center">2-37</entry><entry align="center">39</entry><entry align="center">Henriksson et al, 2002</entry></row><row><entry align="center">11.6± 6.6 (overall CF population)</entry><entry align="center">1-28</entry><entry align="center">56</entry><entry align="center">Jorissen <i>et al.,</i> 1999</entry></row><row><entry align="center">N/A</entry><entry align="center">&lt;2-15 yrs</entry><entry align="center">36</entry><entry align="center">Sekano <i>et al.,</i> 2007</entry></row></tbody></tgroup></table></tables>
Although polyps are commonly reported in CF children aged 5-14 years, they can also develop in older CF patients (<nplcit id="ncit0012" npl-type="b"><text>Sheahan, RJ. Harvey and RJ Schlosser, Nasal polyps in Cystic Fibrosis. Book chapter Nasal Polyps: pathogenesis, medical and surgical treatment. 2010: 145-152</text></nplcit><i>;</i> <nplcit id="ncit0013" npl-type="s"><text>Kerrebijn et al., Eur Respir J. 1992;5:1239-42</text></nplcit><i>;</i><nplcit id="ncit0014" npl-type="s"><text> Hadfield et al., Clin Otolaryngol Allied Sci. 2000;25:19-22</text></nplcit><i>;</i> and <nplcit id="ncit0015" npl-type="s"><text>Becker et al., Am J Rhinol 2007; 21:478-482</text></nplcit>), and the prevalence of nasosinusal polyposis in the adult and adolescent CF population has been described to be as high as 44-45% (Kerrebijn <i>et al.,</i> 1992 and <nplcit id="ncit0016" npl-type="s"><text>Brihaye et al., Int J Pediatr Otorhinolaryngol. 1994 Jan;28(2-3):141-7</text></nplcit><i>).</i> Therefore, it is estimated that approximately 6,000-7,000 adults and children 12 years of age and older in the US have nasal polyps complicating CF.</p><p id="p0004" num="0004">In patients with CF, intracellular water flux increases mucous viscosity, leading to mucociliary dysfunction, stasis, and nasosinusal obstruction (<nplcit id="ncit0017" npl-type="s"><text>Batsakis and El-Naggar, Ann. Otol. Rhinol. Laryngol., 105:329-330, 1996</text></nplcit>). This predisposes the CF patient to bacterial colonization, mainly by <i>Pseudomonas</i> and <i>Staphylococcus</i> species, and results in chronic infection. However, the current cause of nasal polyps in cystic fibrosis patients is unknown.</p><p id="p0005" num="0005">The symptoms of nasosinusal polyposis in CF include nasal obstruction, nasal congestion, rhinorrhea, sinusitis, cough, headache, facial pain, disordered sleep, anosmia and secondary infection (Pimenta <i>et al.,</i> 2008; Hadfield <i>et al.,</i> 2000; Sheahan <i>et al.,</i> 2010; and <nplcit id="ncit0018" npl-type="s"><text>Gysin et al., Pediatr Pulmonol 2000; 30:481-489</text></nplcit>). These symptoms are often underestimated due to the priority given to the more severe manifestations of<!-- EPO <DP n="3"> --> cystic fibrosis, such as pulmonary infections and nutritional impairment (Pimenta <i>et al.,</i> 2008). Because patients may adapt to their nasosinusal symptoms, these may go unreported and thus untreated, despite the fact that otorhinolaryngological manifestations of the disease can interfere with quality of life and may have a role in the overall progression of CF (Piment <i>et al.,</i> 2008). There is some evidence of a correlation between upper airway abnormalities and lung disease in CF patients (<nplcit id="ncit0019" npl-type="s"><text>Friedman and Stewart, Am. J. Rhinol., 20:568-72, 2006</text></nplcit>), and the paranasal sinuses may serve as a source for <i>Pseudomonas</i> aeruginosa-induced lung infections in CF (<nplcit id="ncit0020" npl-type="s"><text>Fokkens et al., Rhinology 45; suppl. 20: 1-139</text></nplcit><i>).</i> This association between <i>Pseudomonas</i> respiratory colonization and the presence of nasal polyposis may contribute to the higher annual rates of cystic fibrosis-related acute exacerbations and hospitalizations observed in some clinical trials in CF patients with polyposis in comparison to CF patients without polyposis (<nplcit id="ncit0021" npl-type="s"><text>Cimmino et al., Clin Otolaryngol 2003; 28:125-132</text></nplcit>)<i>.</i></p><p id="p0006" num="0006">Current medical treatments employed in nasosinusal polyposis in CF include topical nasal steroids, oral steroids, nasal irrigations, antibiotics, decongestants, and mucolytics (Sheahan <i>et al.,</i> 2010). In advanced cases, surgical debridement may also be required to remove the polyps and restore sinus ventilation. However, these treatments are often unsatisfactory.</p><p id="p0007" num="0007">Topical intranasal corticosteroids have been used as long-term monotherapy in mild cases or in combination with systemic corticosteroids and/or surgery in more severe cases (<nplcit id="ncit0022" npl-type="s"><text>Mygind and Lund, Treat Respir Med. 2006; 5:93-102</text></nplcit>). When CF polyps are small, use of topical intranasal steroids usually results in temporary polyp shrinkage and reduction of the associated symptoms (Henriksson <i>et al.,</i> 2002). However, steroids block inflammation at a high level and typically temporarily reduce, but do not eliminate, these nasal polyps in CF patients. Moreover, many CF patients with polyposis commonly do not respond to steroids at all (<nplcit id="ncit0023" npl-type="s"><text>McClay, Nasal Polyps, E-medicine specialties review, Updated: Oct. 22, 2008. http://emedicine.medscape.com/article/994274-treatment</text></nplcit>; and <nplcit id="ncit0024" npl-type="s"><text>Scadding, Curr Allergy Asthma Rep. 2002;2:494-9</text></nplcit><i>).</i> Indeed, in the only prospective trial available in the literature that evaluated topical corticosteroid treatment for nasal polyps in adult patients with CF, no significant improvement in symptoms was observed in the steroid-treated group compared with placebo treatment (<nplcit id="ncit0025" npl-type="s"><text>Hadfield et al., Rhinology. 2000;38:63-5</text></nplcit>). The historically poor symptomatic response to steroids may be one of the reasons why clinical development programs that have evaluated topical steroids in nasal polyposis (<i>i.e.,</i> mometasone furoate, beclomethasone diproprionate) excluded patients<!-- EPO <DP n="4"> --> with CF from the studied populations (<nplcit id="ncit0026" npl-type="s"><text>Pär Stjärne et al., Arch Otolaryngol Head Neck Surg. 2006;132:179-185</text></nplcit> and <nplcit id="ncit0027" npl-type="s"><text>Small et al., Allergy Clin Immunol 2005;116:1275-81</text></nplcit>).</p><p id="p0008" num="0008">Administration of steroids also has unwanted and potentially severe side effects. When administered intranasally, steroids can cause thinning of the nasal mucosa and subsequent bleeding. When administered systemically for long periods of time, steroids may have severe side effects, including elevation of blood pressure, insomnia, agitation, psychosis, increased susceptibility to infection, easy bruising, weight gain, osteoporosis and joint damage, hyperglycemia and worsening diabetes, cataracts, and muscular weakness.</p><p id="p0009" num="0009">Since nasal polyps in CF patients are commonly non-responsive to standard steroid therapy, surgical debridement is often necessary (Gysin <i>et al.,</i> 2000). Indeed, polyp surgery is the second most common class of operations performed in CF patients (Henriksson <i>et al.,</i> 2002). However, due to a high tendency for polyps to recur (about 60% of patients have symptomatic recurrence within 18 months following polypectomy), repeated sinus surgery (including endoscopic surgery) is often needed to provide symptomatic relief (Henriksson <i>et al.,</i> 2002). Moreover, debridement risks include injury to the eye or brain, spinal fluid leak, loss of sense of smell and nosebleeds.</p><p id="p0010" num="0010">Thus, no anti-inflammatory drugs currently approved for the treatment of nasal polyps have been successful in treating patients with nasosinusal polyps complicating cystic fibrosis. Accordingly, nasal polyps in cystic fibrosis patients are a problem of major clinical concern for which effective treatments are currently lacking.</p><heading id="h0003"><b>Summary of the Invention</b></heading><p id="p0011" num="0011">It has now surprisingly been found that zileuton ((±)-1-(1-Benzo[b]thien-2-ylethyl)-l-hydroxyurea), an inhibitor of 5-lipoxygenase, can be used to effectively treat nasal polyps in patients having cystic fibrosis. Zileuton has the following chemical structure:
<chemistry id="chem0001" num="0001"><img id="ib0001" file="imgb0001.tif" wi="54" he="24" img-content="chem" img-format="tif"/></chemistry></p><p id="p0012" num="0012">The present invention provides methods of treating nasal polyps in a patient having cystic fibrosis comprising administering to the patient an effective amount of zileuton. In one embodiment, the patient has previously been treated with a steroid.<!-- EPO <DP n="5"> --></p><p id="p0013" num="0013">In another aspect, the invention provides methods of treating nasal polyps in a patient having cystic fibrosis comprising administering to the patient an effective amount of zileuton and an effective amount of a steroid. In one embodiment, the steroid is administered to the patient for a period of time sufficient to reduce the size of the nasal polyps by at least 50%. In another embodiment, the administration of zileuton is begun after the 50% reduction in size of the nasal polyps. In another embodiment, the administration of the steroid and zileuton is concurrent, and administration of zileuton is continued after the 50% reduction in size of the nasal polyps for a period of time sufficient to maintain the size reduction of the polyps. In yet another embodiment, the steroid is administered for a period of time sufficient to reduce the size of the nasal polyps by at least 75%, and administration of zileuton is begun after the 75% reduction in size of the nasal polyps. In another embodiment, the steroid is administered for a period of time sufficient to reduce the size of the nasal polyps by at least 90%, and administration of zileuton is begun after the 90% reduction in size of the nasal polyps.</p><p id="p0014" num="0014">In another aspect, the invention provides methods of treating nasal polyps in a patient having cystic fibrosis comprising i) debriding the nasal polyps; and ii) administering to the patient an effective amount of zileuton. In one embodiment, the method further comprises administering an effective amount of a steroid to the patient. In another embodiment, the zileuton is administered for a period of time sufficient to reduce the risk of recurrence of nasal polyps.</p><p id="p0015" num="0015">In one embodiment, zileuton is substantially free of (S)-zileuton. In another embodiment, zileuton is administered at a dose of about 450 milligrams to about 2400 milligrams per day. In another embodiment, zileuton is administered at a dose of about 600 milligrams per day. In yet another embodiment, zileuton is administered at a dose of about 1200 milligrams per day. In another embodiment, zileuton is administered at a dose of about 2400 milligrams per day.</p><p id="p0016" num="0016">In one embodiment, zileuton is administered orally. In another embodiment, zileuton is administered as a single daily dose. In another embodiment, zileuton is administered twice per day. In another embodiment, zileuton is administered for at least four weeks.</p><p id="p0017" num="0017">In one embodiment, zileuton comprises zileuton that is at least 70% by weight (R)-zileuton and 10% by weight or less of (S)-zileuton, wherein said percent is based on the total weight of zileuton administered.</p><p id="p0018" num="0018">In one embodiment, the steroid is a steroid nasal spray. In another embodiment, the steroid nasal spray is fluticasone, budesonide, flunisolide, mometasone, triamcinolone, or beclomethasone.<!-- EPO <DP n="6"> --></p><p id="p0019" num="0019">In another embodiment, the steroid is an oral steroid. In one embodiment, the oral steroid is prednisolone, prednisone, methylprednisolone or dexamethasone.</p><p id="p0020" num="0020">In another aspect, the invention provides methods of reducing the likelihood of developing nasal polyps in a patient having cystic fibrosis and a <i>Pseudomonas</i> infection comprising administering to the patient an effective amount of zileuton.</p><p id="p0021" num="0021">In another aspect, the invention provides methods of reducing the likelihood of developing nasal polyps in a patient having cystic fibrosis comprising testing the patient for a <i>Pseudomonas</i> infection and, wherein the patient has a <i>Pseudomonas</i> infection, administering a therapeutically effective amount of zileuton to the patient for a period of time sufficient to reduce the likelihood of development of nasal polyps.</p><heading id="h0004"><b>Detailed Description of the Invention</b></heading><p id="p0022" num="0022">The present invention provides methods of treating nasal polyps in a patient having cystic fibrosis by administering to the patient an effective amount of zileuton. The invention is based, at least in part, on the surprising discovery that zileuton can be used to decrease the size of nasal polyps, number of nasal polyps, and/or severity of symptoms of nasal polyps in a patient having cystic fibrosis without the unwanted side effects and high rates of reoccurrence associated with current medical treatments, such as steroids and surgical debridement.</p><p id="p0023" num="0023">The method of treating cystic fibrosis patients with nasal polyps includes a monotherapy, e.g., wherein zileuton is the only pharmaceutically active agent being used to treat the nasal polyps. This embodiment consists essentially of administering an effective amount of zileuton to the patient. "Consisting essentially of" in this context excludes steroid administration and/or surgical intervention, but includes other medical treatments, such as administering other pharmaceutically active agents commonly used in the management of systems of cystic fibrosis other than nasal polyps. In one embodiment, the patient has previously been treated with steroids, and the steroid treatment was ineffective. In another embodiment, the nasal polyps are characterized by the presence of neutrophils.</p><p id="p0024" num="0024">Zileuton is administered for a period of time sufficient to reduce the size of the nasal polyps and/or to reduce the number of the nasal polyps by at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%, or for a period of time sufficient to reduce the size and/or number of nasal polyps below the limits of detection. The size and/or number of nasal polyps can be assessed using methods well known to one of ordinary skill in the art. As an example, nasal polyps can be<!-- EPO <DP n="7"> --> graded by size and number in both the left and right nasal fossa on a scale of 0 to 3 (0= no polyps; 1 = polyp in the middle meatus, not reaching below the inferior border of the middle turbinate; 2 = polyp reaching below the inferior border of the middle turbinate but no the inferior border of the inferior turbinate; and 3 = large polyp reaching to or below the lower border of the inferior turbinate or polyps medial to the middle turbinate; the sum of the left and right nasal fossa polyp scores giving the total bilateral polyp grade) as described by<nplcit id="ncit0028" npl-type="s"><text> Small et al., J. Allergy Clin. Immunol., 116(6):1275-1281, 2005</text></nplcit>.</p><p id="p0025" num="0025">In another embodiment, zileuton is administered for a period of time sufficient to decrease the severity of symptoms of the nasal polyps by at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100%. Nasal polyp symptoms, such as nasal congestion or obstruction, loss of sense of smell, anterior rhinorrhea, and postnasal drip, can be assessed using methods well known to one of ordinary skill in the art. As an example, nasal polyp symptoms can be graded on a scale of 0 to 3 (0= none; 1 = mild; 2 = moderate; 3 = severe), or by using peak nasal inspiratory flow (PNIF) as described by <nplcit id="ncit0029" npl-type="s"><text>Small et al., J. Allergy Clin. Immunol., 116(6):1275-1281, 2005</text></nplcit>. As another example, nasal polyp symptoms can be assessed using the Nasal Obstruction Symptom Evaluation (NOSE) Scale, as described by <nplcit id="ncit0030" npl-type="s"><text>Stewart et al., Otolaryngology - Head and Neck Surgery, 130(2): 157-163, 2004</text></nplcit>.</p><p id="p0026" num="0026">More preferably, zileuton administration is continued for a period of time sufficient to prevent or reduce the likelihood of the reoccurrence of the nasal polyps. Exemplary time periods include one week, two weeks, three weeks, four weeks, five weeks, six weeks, seven weeks, eight weeks, three months, four months, five months, six months, seven months, eight months, nine months, ten months, eleven months, twelve months, thirteen months, fourteen months, fifteen months, sixteen months, seventeen months, eighteen months, one year, two years, three years, or for life. For example, a patient's treatment could be initiated and maintained at a total daily dose of about 2400 mg of zileuton per day for a period of 18 months; or about 900 to about 1200 mg of (R)-zileuton per day for 18 months.</p><p id="p0027" num="0027">Alternatively, zileuton is administered in combination with surgical debridement. As used herein, "debride" and/or "debriding" refer to the surgical removal of nasal polyp tissue. A nasal polyp can be surgically debrided using a small mechanical suction device or microdebrider. Alternatively, a nasal polyp can be surgically debrided using an endoscope. Debridement is also referred to as "polypectomy" and is normally performed on an outpatient basis. Typically, the nasal polyps are first removed by surgical debridement and zileuton is then administered after surgery to prevent or reduce the likelihood of reoccurrence of the nasal polyps. Time periods after surgery<!-- EPO <DP n="8"> --> that are sufficient to reduce the likelihood of reoccurrence include one week, two weeks, three weeks, four weeks, five weeks, six weeks, seven weeks, eight weeks, three months, four months, five months, six months, seven months, eight months, nine months, ten months, eleven months, twelve months, thirteen months, fourteen months, fifteen months, sixteen months, seventeen months, eighteen months, one year, two years, three years, or for life.</p><p id="p0028" num="0028">In another alternative, zileuton administration is combined with steroid therapy, <i>i.e.,</i> the patient with the nasal polyps is administered an effective amount of zileuton and an effective amount of a steroid. In one embodiment, the steroid is a steroid nasal spray, such as fluticasone, budesonide, flunisolide, mometasone, triamcinolone, or beclomethasone. In another aspect, the steroid is an oral steroid, such as prednisolone, prednisone, dexamethasone, or methylprednisolone. Typically, zileuton and the steroid are initially administered concurrently, and the steroid therapy is terminated once the size and/or number of nasal polyps have been reduced by at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or below detection levels. In another embodiment, zileuton and the steroid are initially administered concurrently, and the steroid therapy is terminated once the symptoms of the nasal polyps have decreased in severity by at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100%. Treatment with zileuton is then continued for a period of time sufficient to maintain the size or symptom reduction, or to prevent or reduce the likelihood of reoccurrence or regrowth. Time periods after termination of steroid administration that are sufficient to maintain the size or symptom reduction, or to reduce the likelihood of reoccurrence or regrowth, include one week, two weeks, three weeks, four weeks, five weeks, six weeks, seven weeks, eight weeks, three months, four months, five months, six months, seven months, eight months, nine months, ten months, eleven months, twelve months, thirteen months, fourteen months, fifteen months, sixteen months, seventeen months, eighteen months, one year, two years, three years, or for life.</p><p id="p0029" num="0029">In yet another alternative, a therapeutically effective amount of a steroid is administered to the patient. The steroid therapy is terminated once the size and/or number of nasal polyps have been reduced by at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or below detection levels. In another embodiment, the steroid therapy is terminated once the symptoms of the nasal polyps have decreased in severity by at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100%. After this size, number or symptom reduction has been achieved, a therapeutically effective amount of zileuton is<!-- EPO <DP n="9"> --> administered to the patient to maintain the reduction or to prevent or reduce the likelihood of reoccurrence or regrowth. Time periods after termination of steroid administration that are sufficient to maintain the size, number or symptom reduction or to reduce the likelihood of reoccurrence or regrowth include one week, two weeks, three weeks, four weeks, five weeks, six weeks, seven weeks, eight weeks, three months, four months, five months, six months, seven months, eight months, nine months, ten months, eleven months, twelve months, thirteen months, fourteen months, fifteen months, sixteen months, seventeen months, eighteen months, one year, two years, three years, or for life.</p><p id="p0030" num="0030">In another alternative, the invention provides a method of preventing or reducing the likelihood of developing nasal polyps in a patient having cystic fibrosis. In one embodiment, the patient has a <i>Pseudomonas</i> infection. Optionally, a patient is tested for a <i>Pseudomonas</i> infection and, wherein the patient has a <i>Pseudomonas</i> infection, administering a therapeutically effective amount of zileuton to the patient for a period of time to prevent or reduce the likelihood of development of nasal polyps. The patient may be tested for <i>Pseudomonas</i> infection by methods known to one of ordinary skill in the art, such as swabbing the nasal passages and culturing the bacteria. In one embodiment, the <i>Pseudomonas</i> infection is present in the upper respiratory tract, the lower respiratory tract, or both the upper and lower respiratory tracts. Time periods that are sufficient to prevent or reduce the likelihood of development of nasal polyps include one week, two weeks, three weeks, four weeks, five weeks, six weeks, seven weeks, eight weeks, three months, four months, five months, six months, seven months, eight months, nine months, ten months, eleven months, twelve months, thirteen months, fourteen months, fifteen months, sixteen months, seventeen months, eighteen months, one year, two years, three years, or for life.</p><p id="p0031" num="0031">Since patients with cystic fibrosis often have chronic <i>Pseudomonas</i> infection, in one embodiment, the zileuton is administered for life. In another embodiment, administration of zileuton is administered even after the <i>Pseudomonas</i> infection is no longer detectable. In yet another embodiment, the zileuton is administered until the <i>Pseudomonas</i> infection is no longer detectable. Optionally, the patient is tested for <i>Pseudomonas</i> infection during the course of treatment with zileuton, and treatment with zileuton is terminated once the <i>Pseudomonas</i> infection is no longer detectable.</p><p id="p0032" num="0032">Zileuton has the chemical structure described above in Formula (I) with one asymmetric center. Zileuton exists as a pair of enantiomers referred to herein as (R)-zileuton and (S)-zileuton. The structure of (R)-zileuton or (+)-zileuton is shown below in Formula (II):<!-- EPO <DP n="10"> -->
<chemistry id="chem0002" num="0002"><img id="ib0002" file="imgb0002.tif" wi="43" he="27" img-content="chem" img-format="tif"/></chemistry></p><p id="p0033" num="0033">The structure of (S)-zileuton or (-)-zileuton is shown below in Formula (III):
<chemistry id="chem0003" num="0003"><img id="ib0003" file="imgb0003.tif" wi="43" he="27" img-content="chem" img-format="tif"/></chemistry></p><p id="p0034" num="0034">In one embodiment, zileuton used in the methods of the invention is substantially free of (S)-zileuton. The phrases "zileuton substantially free of (S)-zileuton" and "(R)-zileuton substantially free of (S)-zileuton" are used interchangeably herein. In one embodiment, zileuton is substantially free of (S)-zileuton if at least 80% by weight of the zileuton is (R)-zileuton, and 20% or less by weight of the zileuton is (S)-zileuton; or if at least 85%, 90%, 95%, 97%, or 99% by weight of the zileuton is (R)-zileuton and 15%, 10%, 5%, 3%, or 1% or less by weight of the zileuton is (S)-zileuton.</p><p id="p0035" num="0035">(R)-zileuton may be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques. Methods for the preparation of racemic zileuton have been described, for example, in <patcit id="pcit0002" dnum="US4873259A"><text>U.S. Patent Nos. 4,873,259</text></patcit> and <patcit id="pcit0003" dnum="US6080874A"><text>6,080,874</text></patcit> and by <nplcit id="ncit0031" npl-type="s"><text>Hisao et al., Tetrahedron Letters, 33(19): 2629-32 (1992</text></nplcit>). (R)-zileuton can be prepared by the resolution of racemic zileuton, such as by using (4S)-4-benzyl-2-oxazolidinone-3-carbonyl chloride (<nplcit id="ncit0032" npl-type="s"><text>Garigipati et al., Tetrahedron Letters, 34(35): 5537-40 (1993</text></nplcit>)). (R)-zileuton can also be chemically resolved using the following: esterification with oxalyl chloride and R-mandelic acid, isolation of the diastereomeric mixture from cold ethyl acetate, hydrolysis of the diastereomer to yield the (R)-zileuton which can then purified by recrystallization. Methods for the enantioselective synthesis of (R)-zileuton have also been described. For example, a method for the preparation of (R)-zileuton using the addition of Grignard reagents to N-glycosyl nitrones has been described (<nplcit id="ncit0033" npl-type="s"><text>Basha et al., J Org. Chem., 59(20), 6103-6 (1994</text></nplcit>)). The enantioselective synthesis of (R)-zileuton has also been described using either L-(+)-lactic acid or a gulofuranose auxiliary (Hsiao <i>et al.,</i> 33: 2629-32 (1992); Roloff <i>et al.,</i> 35(7): 1011-14 (1994)). Furthermore, a method for the preparation of (R)-zileuton is also described in <patcit id="pcit0004" dnum="US5663368A"><text>U.S. Patent No. 5,663,368</text></patcit>, the entire contents of which are incorporated herein by reference.</p><p id="p0036" num="0036">A patient is a human having cystic fibrosis (CF). In one embodiment, the patient is an adult having CF. In yet another embodiment, the patient is an adult under 65<!-- EPO <DP n="11"> --> years of age having CF. In another embodiment, the patient is a child under the age of 18 having CF. In another embodiment, the patient is a child under the age of 12 having CF.</p><p id="p0037" num="0037">An "effective amount" or "therapeutically effective amount" of zileuton and/or a steroid preferably is an amount which, when administered to a patient, results in a decrease in size and/or number of nasal polyps, results in a decrease in severity of nasal polyp symptoms, results in an increase in frequency and duration of nasal polyp symptom-free periods, or reduces the likelihood of impairment or disability due to the nasal polyps. Actual amounts may be varied so as to obtain an amount of the zileuton and/or steroid which is effective to achieve the desired therapeutic response for a particular patient, composition, and mode of administration, without being toxic to the patient. The selected amount will depend upon a variety of pharmacokinetic factors including the activity of the zileuton or the activity of the steroid, the route of administration, the time of administration, the rate of excretion of the zileuton or the steroid, the duration of the treatment, other drugs, compounds and/or materials used in combination with the particular compositions employed, the age, sex, weight, condition, general health and prior medical history of the patient being treated, and like factors well known in the medical arts.</p><p id="p0038" num="0038">In one embodiment, the therapeutically effective amount of zileuton is administered to a patient at a total daily dose from about 450 mg to about 2400 mg per day, from about 450 mg to about 1200 mg per day, from about 500 mg to about 1000 mg per day, or from about 600 mg to about 900 mg per day. In another embodiment, the therapeutically effective amount of zileuton is administered at a total daily dose of about 600 mg per day, about 700 mg per day, about 800 mg per day, about 900 mg per day, about 1000 mg per day, about 1200 mg per day, or about 2400 mg per day. In another embodiment, the zileuton is administered at about 600 mg twice a day (BID). In another embodiment, the zileuton is administered at about 1200 mg twice a day (BID).</p><p id="p0039" num="0039">In yet another embodiment, the zileuton is administered to the patient at about 1200 mg twice a day (BID) for a period of time sufficient to reduce the size of the nasal polyps, and administration of zileuton is continued after the reduction in size of the nasal polyps at about 600 mg twice a day (BID) for a period of time sufficient to maintain the reduction in size of the nasal polyps.</p><p id="p0040" num="0040">Alternatively, since it has recently been found that (R)-zileuton is more efficacious than either of (S)-zileuton and racemic zileuton in inhibiting 5-lipoxygenase activity, (R)-zileuton can be administered at a lower therapeutically effective dose. For<!-- EPO <DP n="12"> --> example, a therapeutically effective amount of (R)-zileuton can be administered to a patient at a total daily dose from about 500 mg to about 1000 mg per day, from about 600 mg to about 900 mg per day, about 600 mg per day, about 900 mg per day, or about 1000 mg per day. The total daily dose of zileuton can be administered as a single dose or as multiple, divided doses. In one embodiment, the total daily dose is administered as a single daily dose. In another embodiment, the total daily dose is administered as two doses.</p><p id="p0041" num="0041">The route of administration of the zileuton and/or steroid depends on the condition to be treated. For example, oral administration may be preferred for treatment of severe NPs, and topical intranasal administration may be preferred to treat mild cases of NPs. The route of administration and the dosage, or amount, of the zileuton to be administered can be determined by the skilled artisan without undue experimentation in conjunction with standard dose-response studies. In one embodiment, the zileuton is administered with a pharmaceutically acceptable excipient. The excipient included with the zileuton of the invention is also chosen based on the expected route of administration of the zileuton in therapeutic applications.</p><p id="p0042" num="0042">The zileuton and/or steroid can be administered by a variety of routes including, but not limited to, nasal, topical, oral, pulmonary, parenteral, buccal, transdermal, intravenous, intramuscular, subcutaneous, and intradermal. In one embodiment the zileuton is administered orally. In another embodiment, the zileuton is administered topically. In another embodiment, the zileuton is administered nasally.</p><p id="p0043" num="0043">In one embodiment, the zileuton and/or steroid of the present invention is administered orally. For the purpose of oral therapeutic administration, the zileuton of the present invention may be incorporated with excipients and used in the form of tablets, troches, capsules, elixirs, suspensions, syrups, wafers, chewing gums and the like. Tablets, pills, capsules, troches and the like may also contain binders, excipients, disintegrating agent, lubricants, glidants, sweetening agents, and flavoring agents. Some examples of binders include microcrystalline cellulose, gum tragacanth or gelatin. Examples of excipients include starch or lactose. Some examples of disintegrating agents include alginic acid, corn starch and the like. Examples of lubricants include magnesium stearate or potassium stearate. An example of a glidant is colloidal silicon dioxide. Some examples of sweetening agents include sucrose, saccharin and the like. Examples of flavoring agents include peppermint, methyl salicylate, orange flavoring and the like. Materials used in preparing these various compositions should be pharmaceutically pure and non-toxic in the amounts used. In another embodiment, the zileuton is administered as a tablet or a capsule.<!-- EPO <DP n="13"> --></p><p id="p0044" num="0044">Various other materials may be present as coatings or to modify the physical form of the dosage unit. For instance, tablets may be coated with shellac, sugar or both. A syrup or elixir may contain, in addition to the active ingredient, sucrose as a sweetening agent, methyl and propylparabens as preservatives, a dye and a flavoring such as cherry or orange flavor, and the like.</p><p id="p0045" num="0045">As used herein, nasally administering or nasal administration includes administering the zileuton to the mucus membranes of the nasal passage or nasal cavity of the patient. As used herein, the zileuton is prepared by well-known methods to be administered, for example, as a nasal spray, nasal drop, suspension, gel, ointment, cream or powder. Administration of the zileuton may also take place using a nasal tampon or nasal sponge.</p><p id="p0046" num="0046">For topical administration, suitable formulations may include biocompatible oil, wax, gel, powder, polymer, or other liquid or solid carriers. Such formulations may be administered by applying directly to affected tissues, for example, a liquid formulation can be administered dropwise to the patient's nose, or a cream formulation can be administered to the nose.</p><p id="p0047" num="0047">The zileuton of the present invention can be administered parenterally such as, for example, by intravenous, intramuscular, intrathecal or subcutaneous injection. Parenteral administration can be accomplished by incorporating the zileuton of the present invention into a solution or suspension. Such solutions or suspensions may also include sterile diluents such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents. Parenteral formulations may also include antibacterial agents such as, for example, benzyl alcohol or methyl parabens, antioxidants such as, for example, ascorbic acid or sodium bisulfite and chelating agents such as EDTA. Buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose may also be added. The parenteral preparation can be enclosed in ampules, disposable syringes or multiple dose vials made of glass or plastic.</p><p id="p0048" num="0048">Transdermal administration includes percutaneous absorption of the zileuton through the skin. Transdermal formulations include patches, ointments, creams, gels, salves and the like.</p><p id="p0049" num="0049">In addition to the usual meaning of administering the formulations described herein to any part, tissue or organ whose primary function is gas exchange with the external environment, for purposes of the present invention, "pulmonary" will also mean to include a tissue or cavity that is contingent to the respiratory tract, in particular, the sinuses. For pulmonary administration, an aerosol formulation containing the zileuton,<!-- EPO <DP n="14"> --> a manual pump spray, nebulizer or pressurized metered-dose inhaler as well as dry powder formulations are contemplated. Suitable formulations of this type can also include other agents, such as antistatic agents, to maintain the disclosed compounds as effective aerosols.</p><p id="p0050" num="0050">A drug delivery device for delivering aerosols comprises a suitable aerosol canister with a metering valve containing a pharmaceutical aerosol formulation as described and an actuator housing adapted to hold the canister and allow for drug delivery. The canister in the drug delivery device has a head space representing greater than about 15% of the total volume of the canister. Often, the compound intended for pulmonary administration is dissolved, suspended or emulsified in a mixture of a solvent, surfactant and propellant. The mixture is maintained under pressure in a canister that has been sealed with a metering valve.</p><p id="p0051" num="0051">In addition to the common dosage forms set out above, the composition of the present invention may also be administered by controlled release means, delivery devices, or both, as are well known to those of ordinary skill in the art, such as those described in <patcit id="pcit0005" dnum="US3845770A"><text>U.S. Patent Nos. 3,845,770</text></patcit>; <patcit id="pcit0006" dnum="US3916899A"><text>3,916,899</text></patcit>; <patcit id="pcit0007" dnum="US3536809A"><text>3,536,809</text></patcit>; <patcit id="pcit0008" dnum="US3598123A"><text>3,598,123</text></patcit>; <patcit id="pcit0009" dnum="US4008719A"><text>4,008,719</text></patcit>; <patcit id="pcit0010" dnum="US5674533A"><text>5,674,533</text></patcit>; <patcit id="pcit0011" dnum="US5059595A"><text>5,059,595</text></patcit>; <patcit id="pcit0012" dnum="US5591767A"><text>5,591,767</text></patcit>; <patcit id="pcit0013" dnum="US5120548A"><text>5,120,548</text></patcit>; <patcit id="pcit0014" dnum="US5073543A"><text>5,073,543</text></patcit>; <patcit id="pcit0015" dnum="US5639476A"><text>5,639,476</text></patcit>; <patcit id="pcit0016" dnum="US5354556A"><text>5,354,556</text></patcit>; and <patcit id="pcit0017" dnum="US5733566A"><text>5,733,566</text></patcit>, the entire contents of each of which are incorporated herein by reference. These pharmaceutical compositions can be used to provide slow or controlled-release of the active ingredient therein using, for example, hydropropylmethyl cellulose in varying proportions to provide the desired release profile, other polymer matrices, gels, permeable membranes, osmotic systems, multilayer coatings, microparticles, liposomes, microspheres, or the like, or a combination thereof. The controlled-release of zileuton may be stimulated by various inducers, for example pH, temperature, enzymes, water, or other physiological conditions or compounds. The term "controlled-release" in the context of the present invention is defined herein as the inclusion in the pharmaceutical composition of a compound or compounds, including polymers, polymer matrices, gels, permeable membranes, liposomes, microspheres, or the like, or a combination thereof, that facilitates the controlled-release of zileuton in the pharmaceutical composition.</p><p id="p0052" num="0052">Certain embodiments of the invention are now described in the paragraphs below.
<ul><li>Paragraph 1. A method of treating nasal polyps in a patient having cystic fibrosis comprising administering to the patient an effective amount of zileuton.<!-- EPO <DP n="15"> --></li><li>Paragraph 2. The method of paragraph 1, wherein the patient has previously been treated with a steroid.</li><li>Paragraph 3. A method of treating nasal polyps in a patient having cystic fibrosis comprising administering to the patient an effective amount of zileuton and an effective amount of a steroid.</li><li>Paragraph 4. The method of paragraph 2 or 3, wherein the steroid is administered to the patient for a period of time sufficient to reduce the size of the nasal polyps by at least 50%.</li><li>Paragraph 5. The method of paragraph 4, wherein the administration of zileuton is begun after the 50% reduction in size of the nasal polyps.</li><li>Paragraph 6. The method of paragraph 4, wherein the administration of the steroid and zileuton is concurrent, and administration of zileuton is continued after the 50% reduction in size of the nasal polyps for a period of time sufficient to maintain the size reduction of the polyps.</li><li>Paragraph 7. The method of paragraph 2 or 3, wherein the steroid is administered for a period of time sufficient to reduce the size of the nasal polyps by at least 75%, and administration of zileuton is begun after the 75% reduction in size of the nasal polyps.</li><li>Paragraph 8. The method of paragraph 2 or 3, wherein the steroid is administered for a period of time sufficient to reduce the size of the nasal polyps by at least 90%, and administration of zileuton is begun after the 90% reduction in size of the nasal polyps.</li><li>Paragraph 9. A method of treating nasal polyps in a patient having cystic fibrosis comprising:
<ul><li>i) debriding the nasal polyps; and</li><li>ii) administering to the patient an effective amount of zileuton.</li></ul></li><li>Paragraph 10. The method of paragraph 9, further comprising administering an effective amount of a steroid to the patient.<!-- EPO <DP n="16"> --></li><li>Paragraph 11. The method of paragraph 9, wherein the zileuton is administered for a period of time sufficient to reduce the risk of recurrence of nasal polyps.</li><li>Paragraph 12. The method according to any one of the preceding paragraphs, wherein the zileuton is substantially free of (S)-zileuton.</li><li>Paragraph 13. The method according to any one of the preceding paragraphs, wherein the zileuton is administered at a dose of about 450 milligrams to about 2400 milligrams per day.</li><li>Paragraph 14. The method according to any one of the preceding paragraphs, wherein zileuton is administered at a dose of about 600 milligrams per day.</li><li>Paragraph 15. The method according to any one of the preceding paragraphs, wherein zileuton is administered at a dose of about 1200 milligrams per day.</li><li>Paragraph 16. The method according to any one of the preceding paragraphs, wherein zileuton is administered orally.</li><li>Paragraph 17. The method according to any one of the preceding paragraphs, wherein zileuton is administered as a single daily dose.</li><li>Paragraph 18. The method according to any one of the preceding paragraphs, wherein zileuton is administered twice per day.</li><li>Paragraph 19. The method according to any one of the preceding paragraphs, wherein zilueton is administered for at least four weeks.</li><li>Paragraph 20. The method according to any one of the preceding paragraphs, wherein zileuton comprises zileuton that is at least 70% by weight (R)-zileuton and 10% by weight or less of (S)-zileuton, wherein said percent is based on the total weight of zileuton administered.</li><li>Paragraph 21. The method according to any one of paragraphs 2-8 or 10, wherein the steroid is a steroid nasal spray.<!-- EPO <DP n="17"> --></li><li>Paragraph 22. The method according to paragraph 21, wherein the steroid nasal spray is fluticasone, budesonide, flunisolide, mometasone, triamcinolone, or beclomethasone.</li><li>Paragraph 23. The method according to any one of paragraphs 2-8 or 10, wherein the steroid is an oral steroid.</li><li>Paragraph 24. The method according to paragraph 23, wherein the oral steroid is prednisolone, prednisone, methylprednisolone or dexamethasone.</li><li>Paragraph 25. A method of reducing the likelihood of developing nasal polyps in a patient having cystic fibrosis and a Pseudomonas infection comprising administering to the patient an effective amount of zileuton.</li><li>Paragraph 26. A method of reducing the likelihood of developing nasal polyps in a patient having cystic fibrosis comprising testing the patient for a Pseudomonas infection and, wherein the patient has a Pseudomonas infection, administering a therapeutically effective amount of zileuton to the patient for a period of time sufficient to reduce the likelihood of development of nasal polyps.</li></ul></p><heading id="h0005"><b>EXAMPLES</b></heading><p id="p0053" num="0053">The present invention is further illustrated by the following examples, which should not be construed as further limiting. The contents of all figures and all references, patents and published patent applications cited throughout this application, as well as the Figures, are expressly incorporated herein by reference in their entirety.</p><heading id="h0006"><u>Example 1</u></heading><p id="p0054" num="0054">A 16 year old female patient has a history of cystic fibrosis and chronic sinusitis. The patient complained of hyposmia and nasal congestion. Nasal endoscopy demonstrated bilateral nasal polyposis and purulence. Culture of the sinuses grew out <i>Pseudomonas.</i> Patient was prescribed ciprofloxacin per the sinus culture. Patient did not want to be on oral prednisone for the nasal polyps so zileuton was prescribed for the nasal polyposis. Prior to prescribing oral zileuton, a liver function test was performed that was normal. Patient was given zileuton 1200 mg BID. Two months later patient came back with improved nasal congestion and smell. Nasal endoscopy demonstrated no purulence and decreased polyps while on zileuton. Interestingly, the patient did not take the oral ciprofloxacin that was prescribed. Patient did have<!-- EPO <DP n="18"> --> increased coughing with the zileuton 1200 mg BID, so the prescription was decreased to 600 mg BID. Since the patient's symptoms improved, the zileuton was eventually discontinued. After a few months the patient's sinus infection returned. Patient was placed on oral ciprofloxacin. Patient had initial improvement but eventually had return of her nasal symptoms, so the zileuton was restarted at 600 mg BID.</p><heading id="h0007"><u>Example 2</u></heading><p id="p0055" num="0055">A 5 year old male had a history of cystic fibrosis and chronic sinusitis. Patient failed medical treatment, so he underwent endoscopic sinus surgery. Patient's sinus culture has grown MRSA and <i>Pseudomonas.</i> Patient initially did well after the surgery but was readmitted for pulmonary exacerbation. Despite aggressive medical treatment such as inhaled steroid and inhaled dornase alfa, the patient continued to have coughing. Patient was treated with ciprofloxacin for <i>Pseudomonas.</i> Patient's coughing initially improved but gradually returned. Nasal endoscopy was not performed in the child due to his young age. The patient was then treated with zileuton 600 mg BID after a normal liver function test. Patient's coughing improved with the zileuton treatment.</p><heading id="h0008"><b>Equivalents</b></heading><p id="p0056" num="0056">Those skilled in the art will recognize, or be able to ascertain using no more that routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims.</p></description><claims mxw-id="PCLM90460543" lang="EN" load-source="patent-office"><!-- EPO <DP n="19"> --><claim id="c-en-0001" num="0001"><claim-text>Zileuton for use in the treatment of nasal polyps in a patient having cystic fibrosis, wherein zileuton is administered at a dose of from 450 milligrams to 2400 milligrams per day.</claim-text></claim><claim id="c-en-0002" num="0002"><claim-text>The compound for use according to Claim 1, wherein the patient has previously been treated with a steroid.</claim-text></claim><claim id="c-en-0003" num="0003"><claim-text>The compound for use according to Claim 1, wherein the patient is also administered a steroid.</claim-text></claim><claim id="c-en-0004" num="0004"><claim-text>The compound for use according to Claim 3, wherein the administration of the steroid and zileuton is concurrent, and administration of zileuton is continued after the 50% reduction in size of the nasal polyps for a period of time sufficient to maintain the size reduction of the polyps.</claim-text></claim><claim id="c-en-0005" num="0005"><claim-text>The compound for use according to Claim 3, wherein the steroid is administered for a period of time sufficient to reduce the size of the nasal polyps by at least 90%, and administration of zileuton is begun after the 90% reduction in size of the nasal polyps.</claim-text></claim><claim id="c-en-0006" num="0006"><claim-text>The compound for use according to Claim 1 or Claim 3, wherein zileuton is administered after the nasal polyps have been debrided.</claim-text></claim><claim id="c-en-0007" num="0007"><claim-text>The compound for use according to any one of the preceding claims, wherein zileuton is substantially free of (S)-zileuton.</claim-text></claim><claim id="c-en-0008" num="0008"><claim-text>The compound for use according to any one of the preceding claims, wherein zileuton is administered at a dose of about 1200 milligrams.</claim-text></claim><claim id="c-en-0009" num="0009"><claim-text>The compound for use according to any one of the preceding claims, wherein zileuton is administered at a dose of about 600 milligrams.</claim-text></claim><claim id="c-en-0010" num="0010"><claim-text>The compound for use according to any one of the preceding claims, wherein zileuton is administered as a single daily dose, or wherein zileuton is administered twice per day.<!-- EPO <DP n="20"> --></claim-text></claim><claim id="c-en-0011" num="0011"><claim-text>The compound for use according to any one of the preceding claims, wherein zileuton is administered for at least four weeks.</claim-text></claim><claim id="c-en-0012" num="0012"><claim-text>The compound for use according to any one of Claims 2 to 5, wherein the steroid is a steroid nasal spray or an oral steroid.</claim-text></claim><claim id="c-en-0013" num="0013"><claim-text>The compound for use according to Claim 12, wherein the steroid nasal spray is fluticasone, budesonide, flunisolide, mometasone, triamcinolone, or beclosmethasone, or wherein the oral steroid is prednisolone, prednisone, methylprednisolone, or dexamethasone.</claim-text></claim><claim id="c-en-0014" num="0014"><claim-text>Zileuton for use in reducing the likelihood of developing nasal polyps in a patient having cystic fibrosis and a Pseudomonas infection, wherein zileuton is administered at a dose of from 450 milligrams to 2400 milligrams per day.</claim-text></claim><claim id="c-en-0015" num="0015"><claim-text>The compound for use according to Claim 14, comprising testing the patient for a <i>Pseudomonas</i> infection.</claim-text></claim></claims><search-report-data><doc-page id="srep0001" file="srep0001.tif" wi="163" he="233" type="tif"/><doc-page id="srep0002" file="srep0002.tif" wi="163" he="233" type="tif"/><doc-page id="srep0003" file="srep0003.tif" wi="163" he="233" type="tif"/></search-report-data><copyright>User acknowledges that Fairview Research LLC and its third party providers retain all right, title and interest in and to this xml under applicable copyright laws.  User acquires no ownership rights to this xml including but not limited to its format.  User hereby accepts the terms and conditions of the Licence Agreement</copyright></patent-document>
